Welcome to our dedicated page for Cannapharmarx SEC filings (Ticker: CPMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CannaPharmaRX, Inc. (CPMD) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Forms 10‑K, 10‑Q, and 8‑K. These documents offer detailed information on CannaPharmaRX’s cannabis cultivation operations in Canada, its international export activities, financial condition, and risk factors. Investors can review how the company describes its business strategy, facility capacity, licensing status, and relationships with key customers and partners.
Recent 8‑K filings highlight several important developments. One filing reports that the failure‑to‑file cease trade order issued by the British Columbia Securities Commission was revoked effective December 12, 2025, after the company completed its delinquent Canadian and U.S. filings. The same 8‑K outlines substantial doubt about CannaPharmaRX’s ability to continue as a going concern, citing a working capital deficiency and significant related party debt, and describes a strategic plan to negotiate with creditors, secure working capital, increase production at the Cremona, Alberta facility, and expand in European markets.
Another 8‑K addresses payment schedule agreements with significant debtholders, while additional filings report the extinguishment of convertible notes and the resignation of a board member. Together with periodic reports, these filings show how CannaPharmaRX is managing its capital structure, debt obligations, and governance as it develops its cannabis business.
On Stock Titan, SEC filings for CPMD are updated from EDGAR and can be paired with AI‑powered summaries that explain the key points in plain language. Users can quickly identify disclosures related to going‑concern language, debt restructuring, facility expansion plans, licensing and certification status, and other material events that affect CannaPharmaRX’s risk profile and operations.
CannaPharmaRX, Inc. reported that director Rick Orman resigned from its Board of Directors effective immediately on January 8, 2026. The company states that his resignation did not result from any dispute or disagreement with the company or the Board regarding operations, policies, or practices.
The company also noted that on January 12, 2026, it issued a press release providing corporate updates and outlining its 2026 growth strategy, which has been furnished as an exhibit to this report.
CannaPharmaRX, Inc. reports that the BC Securities Commission has revoked its failure-to-file cease trade order, effective December 12, 2025, after the company completed its previously delinquent Canadian and U.S. filings. The order had stemmed from missing annual financial statements and related disclosures for the year ended December 31, 2022.
Despite this regulatory step, the company highlights substantial doubt about its ability to continue as a going concern. It reports a working capital deficiency of $27,009,769 and related party debt of $10,762,898 with accrued interest of $3,248,127 as of September 30, 2025. Management’s plan includes negotiating debt restructurings, seeking additional working capital, ramping cannabis production at its Cremona, Alberta facility beyond the current six of ten operating grow rooms, and expanding into European markets such as Germany and Israel, supported by a planned EU-GMP certification application.
CannaPharmaRx (CPMD) filed its Q3 2025 report, showing rising sales but continued losses and severe liquidity strain. Revenue reached $656,606 in the quarter (up from $312,164), yet the company posted a gross loss of $440,000 and a net loss of $1,477,811. For the nine months, revenue was $1,223,533 with a net loss of $3,581,863. Cash was $927, total liabilities were $34,133,650, and shareholders’ deficit was $22,516,743. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
On August 7, 2025, the company formalized repayment plans with Koze and affiliates and with Mr. Tal: as of June 30, 2025, about $10 million was owed to Koze and about $0.7 million to Mr. Tal, with interest revised to 6% per annum and 60% of all future profits and capital raised allocated toward repayment. The company is also in default under a royalty/security agreement tied to cannabis sales; Koze agreed to forbear until December 31, 2025. Operations rely on a Formosa lease, with unpaid lease amounts accumulating and a related promissory note now at 6%. Shares outstanding were 662,501,405 as of November 14, 2025.
CannaPharmaRX, Inc. entered into letter agreements that set out payment schedules to address outstanding amounts owed to two significant debtholders. The company states that these schedules are intended to manage existing debt, avoid additional defaults, and still retain capital to grow operations and deliver product. The agreements and their terms had already been described in the company’s quarterly report for the period ended June 30, 2025, but the actual schedule documents were mistakenly omitted. This report is being used to file those repayment schedule agreements as exhibits so they are formally included in the public record.
FAQ
What is the current stock price of Cannapharmarx (CPMD)?
What is the market cap of Cannapharmarx (CPMD)?
